Does Geisinger Health Plan Cover Eliquis?

What Eliquis Is and Why Coverage Decisions Matter

Eliquis (apixaban) is an oral Factor Xa inhibitor approved by the FDA for five distinct indications: reducing stroke risk in non-valvular atrial fibrillation, treating deep vein thrombosis (DVT), treating pulmonary embolism (PE), preventing recurrent DVT and PE, and preventing VTE following hip or knee replacement surgery. The FDA approved apixaban in December 2012 under NDA 202155. [1]

Why Apixaban Has Become the Dominant DOAC

The ARISTOTLE trial (N=18,201) found that apixaban reduced the rate of stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year; P<0.001 for superiority), while also reducing major bleeding by 31% (2.13% vs. 3.09% per year; P<0.001). [2] Those dual advantages, fewer strokes and less bleeding, explain why clinicians now prescribe apixaban more frequently than warfarin for non-valvular AFib. The 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation states: "For patients with AF and elevated stroke risk, DOACs are recommended over warfarin." [3]

The Financial Stakes for Patients

Without insurance coverage, a 30-day supply of Eliquis 5 mg twice daily (the standard AFib dose) can exceed $600 at retail pharmacies. That cost is not hypothetical. For a Geisinger member denied coverage or placed on a non-preferred tier, monthly out-of-pocket spending may reach $150 to $300 even with insurance, depending on deductible status. Understanding the exact coverage pathway before filling the first prescription protects patients from surprise costs and treatment gaps.

How Geisinger Health Plan Organizes Its Formulary

Geisinger Health Plan (GHP) is an integrated insurer tied to the Geisinger Health System, serving commercial, Medicare Advantage (Geisinger Gold), and Medicaid members primarily in Pennsylvania. The formulary is organized into tiers, and the tier assigned to Eliquis determines cost-sharing.

Tier Structure Overview

GHP commercial plans typically use a 4- to 5-tier structure:

• Tier 1 covers generic preferred drugs with the lowest copay (often $5 to $15).
• Tier 2 covers generic non-preferred or low-cost preferred brands.
• Tier 3 covers preferred brand-name drugs. Copays commonly run $45 to $75 per 30-day fill.
• Tier 4 covers non-preferred brand-name drugs. Copays often fall between $80 and $150, or a coinsurance percentage applies.
• Tier 5 (where present) covers specialty drugs with the highest cost-sharing.

Eliquis sits at Tier 3 on many GHP commercial formularies and at Tier 4 on some plan variants, depending on the plan year and employer group. Because no FDA-approved generic apixaban exists as of January 2025, GHP cannot automatically substitute a cheaper equivalent at the pharmacy counter.

Medicare Advantage (Geisinger Gold) Tier Placement

Geisinger Gold Medicare Advantage plans operate under separate Part D formularies filed annually with the Centers for Medicare and Medicaid Services. Eliquis tier placement on Part D plans changed nationally after CMS began including certain DOACs in the protected-class consideration discussions. On most 2024 Geisinger Gold plan variants, Eliquis is covered at a mid-tier level, with a standard Phase benefit copay that the plan's Summary of Benefits document specifies. Members who reach the catastrophic coverage threshold pay no more than $3.30 (generic rate) or $8.20 (brand rate) per fill under the IRA-revised Part D rules effective January 2025. The Inflation Reduction Act Part D redesign, signed August 2022 (Public Law 117-169), caps out-of-pocket drug costs at $2,000 annually for Medicare Part D enrollees beginning 2025. [4]

Prior Authorization Requirements for Eliquis on GHP

Prior authorization (PA) is a formal review process in which GHP's pharmacy team evaluates whether a prescribed drug meets clinical criteria before agreeing to cover it. Most GHP plan types require PA for Eliquis.

What GHP Typically Looks For in a PA Request

GHP's PA criteria for apixaban are not publicly posted in full, but based on standard insurer practice and GHP's publicly available formulary exception guidance, a PA submission generally needs to include:

1. The confirmed FDA-approved diagnosis (e.g., non-valvular AFib documented by ECG or Holter monitor, or imaging-confirmed DVT/PE).
2. The CHA₂DS₂-VASc score for AFib patients (score of 2 or higher in males, 3 or higher in females typically qualifies).
3. Documentation of a contraindication to warfarin, or evidence that warfarin was tried and failed (either due to labile INR, bleeding event, or patient non-compliance with monitoring requirements).
4. Renal function labs (serum creatinine, eGFR) since apixaban dosing adjusts in severe renal impairment and CrCl <15 mL/min is listed as a precaution. [5]
5. Current medication list to flag interactions (e.g., combined P-gp and CYP3A4 inhibitors/inducers that alter apixaban exposure).

Step Therapy and Warfarin

Many GHP commercial plans include a step therapy requirement: the member must try warfarin first (typically 90 days) before GHP will approve Eliquis. This requirement can be waived if the prescriber documents a specific clinical reason warfarin is inappropriate. Clinically valid reasons include a history of warfarin-related intracranial hemorrhage, unstable INR despite adherence, known genetic variants (CYP2C9 or VKORC1) that make dosing unusually difficult, or a patient with significant lifestyle barriers to monthly INR monitoring. CYP2C9 and VKORC1 pharmacogenomic variants affect warfarin dose requirements in approximately 30 to 35% of patients, according to CPIC guideline data. [6]

How Long PA Decisions Take

Federal rules under the No Surprises Act and ACA require non-urgent PA decisions within 72 hours (urgent cases: 24 hours). GHP's member handbook states that standard PA decisions are returned within 3 business days. If the PA is denied, the member has the right to appeal, and the prescriber can request a peer-to-peer review directly with GHP's medical director. CMS finalized rules in January 2024 requiring Medicare Advantage plans to respond to standard PA requests within 7 calendar days and expedited requests within 72 hours, effective 2026. [7]

What to Do if Geisinger Denies Eliquis Coverage

A denial is not a final answer. Several structured pathways exist to obtain coverage or reduce cost.

Step 1: Request a Formal Denial Letter

GHP must provide a written Explanation of Benefits (EOB) or denial notice with the specific reason for denial. The denial letter triggers your right to appeal under ERISA (for employer-sponsored plans) or ACA marketplace rules.

Step 2: Submit a Formulary Exception

A formulary exception asks GHP to cover Eliquis outside its normal tier or PA process because a plan-preferred alternative is medically inappropriate for this specific patient. The prescriber submits clinical notes showing why the formulary alternative (e.g., rivaroxaban or warfarin) cannot be used. The ROCKET AF trial (N=14,264) found rivaroxaban non-inferior to warfarin for stroke prevention in AFib, but apixaban showed superior bleeding outcomes in the ARISTOTLE trial, data that supports a formulary exception when a patient has prior bleeding history. [8]

Step 3: Internal Appeal, Then External Review

If the formulary exception is denied, file a Level 1 internal appeal. GHP must resolve standard Level 1 appeals within 30 days. If the internal appeal fails, Pennsylvania residents can request an external independent review through the Pennsylvania Insurance Department within 4 months of the denial. The external reviewer's decision is binding on GHP.

Step 4: Access Manufacturer Assistance Programs

Bristol-Myers Squibb and Pfizer operate the Eliquis 360 Support program. Commercially insured patients who meet income criteria may pay as little as $10 per month through the co-pay card. Medicare and Medicaid patients cannot legally use the co-pay card but may qualify for the BMS Patient Assistance Foundation if household income falls below 400% of the federal poverty level. The foundation provides Eliquis at no cost to qualifying patients. Patient assistance programs for branded medications reduce adherence barriers; a 2019 analysis in JAMA Internal Medicine found that co-pay card programs increased medication adherence by 8 to 14 percentage points in patients with chronic conditions. [9]

Clinical Alternatives GHP May Prefer Over Eliquis

When a PA is denied and a formulary exception fails, the prescriber must consider whether a formulary-preferred alternative is clinically appropriate.

Rivaroxaban (Xarelto)

Rivaroxaban is another Factor Xa inhibitor with FDA approval for the same core indications as apixaban. Some GHP formularies place rivaroxaban on a lower (preferred) tier than apixaban, making it the path of least resistance for insurance approval. The ROCKET AF trial demonstrated non-inferiority to warfarin (1.7% vs. 2.2% annualized stroke rate; P<0.001 for non-inferiority). [8] The key difference: rivaroxaban is dosed once daily (20 mg with the evening meal for AFib), while apixaban is dosed twice daily (5 mg twice daily for most AFib patients). Once-daily dosing may benefit patients with adherence difficulties, but some physicians prefer the twice-daily apixaban schedule because peak-to-trough concentration fluctuations are smaller.

Dabigatran (Pradaxa)

Dabigatran is a direct thrombin inhibitor, not a Factor Xa inhibitor. The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily reduced stroke/systemic embolism by 34% vs. Warfarin (1.11% vs. 1.69% per year; P<0.001 for superiority). [10] Dabigatran requires dose adjustment for creatinine clearance <30 mL/min and carries a higher rate of GI bleeding compared to apixaban in some analyses. The ARISTOTLE investigators reported that apixaban produced significantly less GI bleeding than warfarin (0.76% vs. 0.86% per year), while dabigatran 150 mg showed increased GI bleeding vs. Warfarin in RE-LY. [11]

Warfarin (Coumadin)

Warfarin remains a Tier 1 drug on virtually every GHP formulary because it is a generic with a 30-day supply costing under $10 at most pharmacies. Its limitations are well-established: narrow therapeutic index, frequent INR monitoring, food and drug interactions affecting the CYP2C9 pathway, and a time-in-therapeutic range (TTR) that averages only 55 to 65% in real-world practice despite best efforts. A 2022 analysis published in Circulation found that patients with TTR below 65% had significantly higher rates of both stroke and major bleeding compared to patients with TTR above 65%. [12] For patients who can maintain a consistently therapeutic INR, warfarin is clinically acceptable. For patients who cannot, the 2023 ACC/AHA AFib guidelines support DOAC use as the preferred strategy. [3]

How to Verify Your Specific GHP Plan's Current Eliquis Coverage

Formularies change annually. The coverage status described here reflects publicly available information as of January 2025 and should be verified directly.

Four Verification Methods

1. GHP online formulary tool: Visit the Geisinger Health Plan website, manage to "Pharmacy / Drug List," select your specific plan year and plan name, and search "apixaban" or "Eliquis."
2. GHP member services phone line: Call 1-800-498-9731 (TTY: 711). Ask the representative to confirm the current tier, PA requirement, and any step therapy edit for apixaban under your plan's benefit year.
3. Your prescribing physician's office: Most cardiology and primary care practices that use Geisinger's integrated EHR system (Epic) have real-time formulary checking built into the prescription workflow through Surescripts. The prescriber can see GHP's coverage decision at the point of prescribing.
4. Pharmacy benefit check: Ask your pharmacist to run a test claim before you commit to the prescription. This reveals the exact cost-sharing at that moment without any obligation to pick up the medication.

What Changes Year to Year

GHP files updated formularies with the Pennsylvania Insurance Commission each fall for the next benefit year. Common year-over-year changes include tier reassignments (a drug moving from Tier 3 to Tier 4 when a preferred alternative becomes available), new PA criteria edits, and changes to quantity limits. Eliquis quantity limits are typically set at 60 tablets per 30-day fill for the 5 mg twice-daily dose and 120 tablets per 30-day fill only with documented clinical justification for higher supply.

The Clinical Case for Apixaban: Why Prescribers Fight for Coverage

Understanding the clinical evidence helps patients and providers build stronger PA appeals.

Stroke Prevention in Atrial Fibrillation

ARISTOTLE (N=18,201) remains the foundational apixaban trial. At 1.8 years median follow-up, apixaban 5 mg twice daily reduced the primary endpoint of stroke or systemic embolism to 1.27% per year vs. 1.60% per year with warfarin (HR 0.79; 95% CI 0.66 to 0.95; P<0.001 for non-inferiority, P=0.01 for superiority). All-cause mortality also fell by 11% (HR 0.89; P=0.047). [2] Those mortality data are not always included in PA letters but can strengthen an appeal significantly.

DVT and PE Treatment

The AMPLIFY trial (N=5,395) tested apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily for 6 months against conventional therapy (enoxaparin plus warfarin) in patients with acute VTE. Apixaban was non-inferior for the primary efficacy outcome (2.3% vs. 2.7%; RR 0.84; 95% CI 0.60 to 1.18; P<0.001 for non-inferiority) and produced 69% less major bleeding (0.6% vs. 1.8%; P<0.001). A single-drug oral regimen without bridging injections reduces both patient burden and nursing home or hospital-based INR monitoring costs, a factor that supports cost-effectiveness arguments in PA appeals. [13]

Extended VTE Prevention

AMPLIFY-EXT (N=2,482) showed that extending apixaban treatment beyond 6 months at either the 2.5 mg or 5 mg twice-daily dose reduced recurrent VTE by approximately 80% compared to placebo, without a statistically significant increase in major bleeding at the 2.5 mg dose. [14] This positions long-term apixaban as the standard of care for patients with unprovoked VTE or ongoing risk factors. The American Society of Hematology 2020 VTE guidelines recommend extended anticoagulation for patients with unprovoked proximal DVT or PE who have a low-to-moderate bleeding risk. [15]

Special Populations: GHP Coverage Considerations

Patients With Chronic Kidney Disease

Apixaban does not require dose reduction until renal function is severely impaired. The standard dose-reduction criteria (to 2.5 mg twice daily) apply when two of three criteria are met: age 80 or older, weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. Patients on dialysis present a separate challenge; the FDA label notes limited data in dialysis patients, and the 2022 KDIGO guidelines suggest that the evidence for DOACs in dialysis-dependent CKD remains insufficient to make a definitive recommendation. KDIGO 2022 CKD Clinical Practice Guideline states caution is warranted in patients with eGFR <15 mL/min due to limited randomized data for all DOACs. [16] GHP PA submissions for dialysis patients should include nephrology notes supporting the choice.

Older Adults (Age 75 and Above)

Adults over 75 face higher stroke risk but also higher bleeding risk. The 2023 ACC/AHA AFib guidelines note that apixaban is preferred over other DOACs in older adults because of its bleeding profile. [3] The ELDERCARE-AF trial (N=984) evaluated edoxaban 15 mg daily in elderly Japanese patients (mean age 86.6) deemed unsuitable for standard anticoagulation; that study provides indirect evidence that even reduced-dose Factor Xa inhibition reduces stroke significantly. [17] GHP's PA criteria may specifically require documentation of bleeding risk assessment using a validated tool such as HAS-BLED.

Post-Surgical VTE Prophylaxis

Following elective total hip or knee replacement, apixaban 2.5 mg twice daily for 10 to 35 days is an FDA-approved prophylaxis regimen. The ADVANCE-2 (N=3,057, knee) and ADVANCE-3 (N=5,407, hip) trials established superiority over enoxaparin for VTE prevention with comparable major bleeding rates. [18] For surgical patients, GHP typically approves a short prophylactic course without the same step therapy requirements that apply to long-term AF management.

HealthRX Clinical Decision Framework: Navigating a GHP Eliquis PA

The following framework summarizes the action sequence a prescriber or patient should follow when GHP requires PA for Eliquis. This framework was developed by the HealthRX medical team based on GHP's published formulary management policies, CMS PA regulations, and the 2023 ACC/AHA AFib guidelines.

Step 1 (Day 0): Submit PA through GHP's online provider portal or fax PA line with diagnosis code, CHA₂DS₂-VASc score, renal function labs, and any warfarin contraindication documentation.

Step 2 (Days 1 to 3): If no response, call GHP pharmacy PA line (1-800-498-9731) for status. Request expedited review if patient is actively anticoagulated or recently discharged for AFib or VTE.

Step 3 (Days 3 to 7): If PA denied, request a peer-to-peer call between the prescribing physician and GHP's medical director. Peer-to-peer reviews overturn denials in roughly 30 to 50% of cases across major insurers according to 2022 AMA prior authorization survey data.

Step 4 (Days 7 to 30): If peer-to-peer fails, file a formal Level 1 internal appeal with the ARISTOTLE mortality data, AMPLIFY bleeding data, and patient-specific bleeding risk score as supporting exhibits.

Step 5 (Day 30 onward): If the Level 1 appeal is denied, escalate to external review through the Pennsylvania Insurance Department. Simultaneously enroll the patient in the BMS/Pfizer Eliquis 360 Support program to prevent a treatment gap during the appeal window.

Cost-Reduction Strategies While Awaiting Coverage

Manufacturer Co-Pay Card

The BMS/Pfizer Eliquis 360 Support co-pay card is available at eliquis.bmscustomerconnect.com. Commercially insured patients (not Medicare or Medicaid) may pay $10 per month for up to a 30-day supply. Enrollment takes roughly 5 minutes online. The card applies at most major retail and mail-order pharmacies. Co-pay assistance programs have been shown to significantly reduce cost-related non-adherence; a 2020 study in the American Journal of Managed Care found that eliminating cost-sharing for anticoagulants reduced treatment discontinuation by 22% in AFib patients over 12 months. [19]

90-Day Mail-Order Supply

GHP's pharmacy benefit typically offers a reduced per-unit cost when members fill a 90-day supply through GHP's mail-order pharmacy partner. Even at Tier 3 or Tier 4, a 90-day fill often carries a lower effective per-pill cost than three consecutive 30-day retail fills.

GoodRx and Discount Cards

GoodRx and similar discount programs cannot be combined with insurance on the same transaction, but they may be cheaper than the insurance copay for members who have not yet met their deductible. A GoodRx coupon for a 60-tablet supply of apixaban 5 mg typically prices between $450 and $550 at major chains as of early 2025, which is roughly equivalent to the uninsured retail price. The co-pay card from BMS/Pfizer will almost always produce a lower out-of-pocket cost for commercially insured patients.